Novo Nordisk reported a decline in adjusted earnings per share and revenue for Q1 2026, primarily due to the exclusion of a one-time US 340B benefit. Despite this, the company's GLP-1 franchise, particularly Wegovy, showed strong volume growth. However, ongoing pricing pressures and margin compression in the US market have led to cautious full-year guidance for 2026. The stock trades at a significant discount compared to sector peers, presenting a potential long-term investment opportunity if volume growth and margin stabilization drive earnings recovery beyond 2026.
Novo Nordisk presented new phase 3 trial data showing that adults taking the Wegovy pill (oral semaglutide 25 mg) achieved meaningful weight loss, with early responders losing up to 21.6% body weight by week 64. Even those not classified as early res...
Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) demonstrated significant weight loss and mobility improvements in adults with obesity in the phase 3 OASIS 4 trial. Nearly 29% of early responders lost an average of 21.6% body weight by week 64, wh...
Novo Nordisk disclosed that two closely associated persons of its CFO, Karsten Munk Knudsen, received 50 shares each as gifts on May 7, 2026. The shares were valued around DKK 294 per share and the transactions occurred outside a trading venue. This ...
Telehealth company Hims & Hers saw its stock fall 15.7% in premarket trading after reporting a first-quarter net loss of $92 million, nearly double last year's $50 million loss. Revenue rose 4% to $608 million, but average monthly revenue per subscri...
Novo Nordisk's Wegovy® (semaglutide) demonstrated significant weight loss averaging 22.6% in premenopausal women and consistent results across all menopause stages, with major reductions in waist circumference. The drug also lowered risks of migraine...
